Efficacy of cognitive functional therapy for pain intensity and disability in patients with non-specific chronic low back pain: a randomised sham-controlled trial.

Objective: This study investigated the efficacy of cognitive functional therapy (CFT) versus a sham procedure for pain intensity and disability for patients with non-specific chronic low back pain (CLBP).

Methods: This is a randomised sham-controlled trial conducted in a primary care public health service. A total of 152 participants were randomly assigned to the CFT group (n=76) and the sham group (n=76).

Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days.

CIGB-500 is a product whose active pharmaceutical ingredient is GHRP-6, (Growth Hormone Releasing Peptide-6), a synthetic peptide that allows the rescue of cardiac mass affected during Acute Myocardial Infarction. The objective of the study was to determine the toxicity profile of CIGB-500 in dogs. As general methodology, CIGB-500 was administered daily to dogs by intravenous route for 28 consecutive days.

Amyotrophic Lateral Sclerosis Associated With Severe Sensory Neuronopathy: Case Series.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system. However, an association with sensory neuronopathy has been scarcely described. We described 3 unrelated patients (2 males) with sporadic spinal-onset ALS and sensory neuronopathy.

Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis.

Objectives: To estimate the relative efficacy and safety of tislelizumab with or without chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in first-line (1L) squamous, 1L non-squamous with programmed death-ligand 1 (PD-L1) ≥ 50 %, and second- and subsequent lines (2L + ) settings via indirect treatment comparisons, following a systematic literature review (SLR) of studies investigating existing anti-programmed cell death protein-(ligand)1 (PD-[L]1) therapies.

Methods: The SLR was originally conducted in 2022 and updated in 2023. A feasibility assessment (FA) was undertaken to assess the assumptions required for network meta-analysis (NMA) among therapies approved in the UK and European Union aligning with tislelizumab's license.

Decreased anxiety-like behavior and trigeminal ganglion BDNF levels persist in rats with temporomandibular joint arthritis even after resolution of the nociceptive process.

In this study, pain- and anxiety-like behaviors, locomotor and exploratory activity, histological and biomarker parameters were evaluated following induction of a temporomandibular joint (TMJ) arthritis model in rats. Twenty-two adult male Wistar rats were assigned to receive either saline (sham group) or Complete Freund's Adjuvant (CFA - pain group) into the right TMJ. Mechanical allodynia was assessed using the facial electronic von Frey (VF) test, while thermal hyperalgesia was assessed using the Orofacial Pain Assessment Device (OPAD) assay.